ReviewMediators of inflammation2019
Implication of IL-17 in Bone Loss and Structural Damage in Inflammatory Rheumatic Diseases.
Review in Mediators of inflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 54 citations in OpenAlex.
- Diallyl Disulfide Mitigates LPS-Induced Inhibition of Osteogenic Differentiation and Alleviates Inflammatory Bone Loss via PI3K/AKT Signaling Pathway.Drug design, development and therapy · 2026Article
- Influence of SARS-CoV-2 reinfection on bone health in the population over 55 years old in Beijing, China: a cross-sectional study.Frontiers in public health · 2026Article
- Secukinumab and Adalimumab on Bone Health in Psoriasis: A Longitudinal Cohort Study.Psoriasis (Auckland, N.Z.) · 2026Article
- Prognostic value of trabecular bone score for major osteoporotic fractures in patients with radiographic axial spondyloarthritis: a 3-year prospective cohort study.Rheumatology international · 2025Article
- The role of taurine in bone metabolism.iScience · 2025Review
- Estrogen loss activates memory T-cells to compromise bone integrity through distinct cortical compartments in mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025Article
- Multi-omics reveals circadian regulation of bone homeostasis by gut microbiota metabolites: mechanisms and chronotherapeutic implications.Frontiers in immunology · 2025Review
- Circulating Baseline CXCR3ACR open rheumatology · 2025Article
- Network Pharmacology Unveils Multi-Systemic Intervention ofEndocrine, metabolic & immune disorders drug targets · 2025Article
- Osteoarthritis versus psoriasis arthritis: Physiopathology, cellular signaling, and therapeutic strategies.Genes & diseases · 2024Review
- Anti-gout and Urate-lowering Potentials of Curcumin: A Review from Bench to Beside.Current medicinal chemistry · 2024Review
- The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis.Immunotherapy · 2024Review
- Serum concentration of dickkopf-related protein 1 (DKK1) in psoriatic arthritis in the context of bone remodelling.Rheumatology international · 2023Review
- Review
- IL-17A inhibits the degradation of RANKL in osteoblasts by inhibiting BCL2-Beclin1-autophagy signaling.In vitro cellular & developmental biology. Animal · 2023Article
- The sodium does not affect joint pain and functional activity of knee osteoarthritis patients.Journal of public health in Africa · 2023Article
- Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA.Rheumatology advances in practice · 2023Article
- Erianin alleviates collagen-induced arthritis in mice by inhibiting Th17 cell differentiation.Open life sciences · 2023Article
- Serum amyloid A proteins reduce bone mass during mycobacterial infections.Frontiers in immunology · 2023Article
- Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab.Rheumatology and therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proinflammatory cytokines play an important role in the systemic and focal bone loss associated with chronic inflammatory diseases. Targeting these cytokines with biologics and small molecules has led to a major improvement of the bone health of patients with inflammatory arthritis. Cytokines from the IL-17 family have been shown to be involved in the pathogenesis of several diseases such as spondyloarthritis, psoriatic arthritis, or psoriasis. IL-17A has been the first described and the most studied. The recent development of targeted therapies against IL-17A or its receptor and their efficacy has confirmed the importance of this cytokine in the development of inflammatory diseases. The aim of this review was to describe the effects of the IL-17 family and more particularly of IL-17A on bone and cartilage tissues. At the cellular level, IL-17A is proosteoclastogenic whereas its effects on osteoblasts depend on the stage of differentiation of these cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.